Relevance of CD49d protein expression as overall survival and progressive disease prognosticator in chronic lymphocytic leukemia
Related Experiment Video
Updated: Jul 10, 2026
From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia
Published on: October 19, 2014
Valter Gattei1, Pietro Bulian, Maria Ilaria Del Principe
1Clinical and Experimental Onco-Hematology Unit, Centro di Riferimento Oncologico, Istituto di Ricovero e Cura a Carattere Scientifico Aviano, Italy. vgattei@cro.it
Insights
High CD49d expression in chronic lymphocytic leukemia (CLL) predicts shorter survival and time to treatment. Detecting CD49d levels offers valuable prognostic information for CLL patients, aiding treatment decisions.
Area of Science:
- Hematology
- Oncology
- Immunology
Background:
- CD49d (alpha4-integrin) expression varies in chronic lymphocytic leukemia (CLL).
- Its prognostic significance compared to established markers is not fully understood.
Purpose of the Study:
- To evaluate CD49d as an independent prognosticator for overall survival and time to treatment (TTT) in CLL.
- To compare CD49d's predictive power against other known CLL prognostic markers.
Main Methods:
- Flow cytometry was used to quantify CD49d expression in 303 CLL patients.
- Statistical analysis, including hazard ratios, assessed CD49d's independent prognostic value for survival and TTT.
- Comparisons were made with CD38, ZAP-70, IGHV mutation status, and other clinical/biologic factors.
Main Results:
- CD49d expression was stable, reproducible, and easily categorized (CD49dlow vs. CD49dhigh).
- CD49d expression strongly correlated with CD38, ZAP-70, and unmutated IGHV.
- CD49d independently predicted overall survival and TTT, refining predictions made by other markers.
- High CD49d was crucial for accurately predicting shorter TTT in high-risk (ZAP-70high, unmutated IGHV) CLL cases.
Conclusions:
- CD49d is a significant independent prognosticator for overall survival and TTT in CLL.
- CD49d detection should be incorporated into routine prognostic assessments for CLL patients.
- CD49d expression may have pathogenetic and therapeutic implications in CLL.
Abstract:
CD49d/alpha4-integrin is variably expressed in chronic lymphocytic leukemia (CLL). We evaluated its relevance as independent prognosticator for overall survival and time to treatment (TTT) in a series of 303 (232 for TTT) CLLs, in comparison with other biologic or clinical prognosticators (CD38, ZAP-70, immunoglobulin variable heavy chain (IGHV) gene status, cytogenetic abnormalities, soluble CD23, beta2-microglobulin, Rai staging). Flow cytometric detection of CD49d was stable and reproducible, and the chosen cut-off (30% CLL cells) easily discriminated CD49dlow from CD49dhigh cases. CD49d, whose expression was strongly associated with that of CD38 (P<.001) and ZAP-70 (P<.001), or with IGHV mutations (P<.001), was independent prognosticator for overall survival along with IGHV mutational status (CD49d hazard ratio, HRCD49d=3.52, P=.02; HRIGHV=6.53, P<.001) or, if this parameter was omitted, with ZAP-70 (HRCD49d=3.72, P=.002; HRZAP-70=3.32, P=.009). CD49d was also a prognosticator for TTT (HR=1.74, P=.007) and refined the impact of all the other factors. Notably, a CD49dhigh phenotype, although not changing the outcome of good prognosis (ZAP-70low, mutated IGHV) CLL, was necessary to correctly prognosticate the shorter TTT of ZAP-70high (HR=3.12; P=.023) or unmutated IGHV (HR=2.95; P=.002) cases. These findings support the introduction of CD49d detection in routine prognostic assessment of CLL patients, and suggest both pathogenetic and therapeutic implications for CD49d expression in CLL.
